



BRUCKNER-TUDERMAN LEENA

Prof. Dr. Leena Bruckner-Tuderman (female)
Department of Dermatology
Medical Center - University Freiburg
Hauptstr. 7
79106 Freiburg, Germany
Phone: +49-761-270-67160
E-mail: leena.bruckner-tuderman@uniklinik-freiburg.de

Head of the Department of Dermatology

Education and Employment Record

Academic Education and University Degrees

- 1995: Board Exam and Habilitation in Dermatology, University of Muenster, Germany (in the EU)
- 1989: Board Exam and Habilitation in Dermatology, University of Zurich, Switzerland
- 1980 – 1983: Postdoctoral Research Fellow, Biocenter, University Basel, Switzerland
- 1977 – 1980: Postdoctoral Research Fellow, Rutgers Medical School, Piscataway, NJ, USA
- 1977: MD/PhD, Expt. Medicine, University of Oulu, Finland
- 1976: MD, University of Oulu, Finland

Employment

- Since 2003: Professor and Chair, Department of Dermatology, Medical Center – University of Freiburg
- 1993 – 2003: Professor / Senior staff member, Dermatology, University of Muenster
- 1984 – 1993: Resident & Senior staff member, Dermatology, University of Zurich

Coordinating Functions (since 2003)

- 2016 – present: Member of the “Forum Health Research” of the German Federal Ministry of Education and Research (BMBF)
- 2016 – present: Co-Program Spokesman Berta-Ottenstein-Program for Clinician Scientists, University of Freiburg
- 2016 – present: Deputy Editor, Journal of Investigative Dermatology
- 2012 – present: Vice President for Medicine, German Research Foundation (DFG)
- 2015 – present: Coordinator: “Repurposing biomolecules for the treatment of epidermolysis bullosa, EBThera” (European E-Rare Program)
- 2008 – 2011: Coordinator, “International Kindler syndrome network – Kindlernet” (European E-Rare Program)
- 2008 – 2013: Fellow and Director of “School of Life Sciences”, Freiburg Institute of Advanced



Studies (FRIAS)

Scholarships / Awards / Honors (selected)

- 2017: Honorary doctorate, University of Oulu, Finland
- 2017: Honorary doctorate, Semmelweis University, Budapest, Hungary
- 2014: Distinguished Investigator Award, International Society of Matrix Biology
- 2012: Member of the Berlin-Brandenburg Academy of Sciences
- 2010: Member of the Heidelberg Academy of Sciences
- 2009: Eva Luise Köhler Prize for Research on Rare Diseases
- 2009: Chair, Gordon Research Conference "Collagens"
- 2008: Rudi Cormane Lecture, European Society for Dermatological Research
- 2007: Member of the German National Academy of Sciences Leopoldina
- 2007: Maria Duran Lectureship from the International Society for Dermatology
- 2002: Chair, Gordon Research Conference "Basement membranes"
- 2000 – 2001: Visiting Professor of Dermatology, Harvard Medical School
- 1994 – 1999: Heisenberg Fellowship from the German Research Foundation (DFG)

Currently funded Projects

1) European E-Rare Program: "Repurposing biomolecules for the treatment of epidermolysis bullosa, EBThera"; 2) DEBRA International: REFLECT – A dual-center prospective exploratory phase II trial to establish safety, tolerability and efficacy of losartan in children with RDEB; 3) DEBRA International: Validation of Ruxolitinib, a FDA-approved pharmacological inhibitor of JAK1/2, as a therapeutic agent for dermal fibrosis and tumor invasion in RDEB; 4) DEBRA International: Anti-fibrotic mode of action and efficacy of TXA127 as disease modifying therapy for RDEB.

Most important publications

1. Nyström A, Bornert O, Kühl T, Gretzmeier C, Thriene K, Dengjel J, Pfister-Wartha A, Kiritsi D, **Bruckner-Tuderman L.** 2018. Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa. *Proc Natl Acad Sci U S A.* 2018 Jan 23;115(4):E705-E714. doi: 10.1073/pnas.1709111115
2. Mittapalli VR, Madl J, Löffek S, Kiritsi D, Kern JS, Römer W, Nyström A, **Bruckner-Tuderman L.** 2016. Injury-driven stiffening of the dermis expedites skin carcinoma progression. *Cancer Res* 76:940-51
3. Kumar V, Behr M, Kiritsi D, Scheffschick A, Grahnert A, Homberg M, Schwieger-Briel A, Jakob T, **Bruckner-Tuderman L**, Magin TM. 2016. Keratin-dependent thymic stromal lymphopoietin expression suggests a link between skin blistering and atopic disease. *J Allergy Clin Immunol* 138:1461-1464
4. Nyström A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, **Bruckner-Tuderman L.** 2015. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. *EMBO Mol Med* 7:1211-28
5. Nyström A, Velati D, Mittapalli VR, Fritsch A, Kern JS, **Bruckner-Tuderman L.** 2013. Collagen VII plays a dual role in wound healing. *J Clin Invest* 123:3498-509
6. Küttner V, Mack C, Rigbolt KT, Kern JS, Schilling O, Busch H, **Bruckner-Tuderman L**, Dengjel J. 2013. Global remodelling of cellular microenvironment due to loss of collagen VII. *Mol*



Syst Biol. 9:657. doi: 10.1038/msb.2013.17

7. Has C, Spartà G, Kiritsi D, Weibel L, Moeller A, Vega-Warner V, Waters A, He Y, Anikster Y, Esser P, Straub BK, Hausser I, Bockenhauer D, Dekel B, Hildebrandt F, **Bruckner-Tuderman L**#, Laube GF#. 2012. Integrin α3 mutations with kidney, lung, and skin disease. *N Engl J Med* 366:1508-14
8. Franzke CW, Cobzaru C, Triantafyllopoulou A, Löffek S, Horiuchi K, Threadgill DW, Kurz T, van Rooijen N, **Bruckner-Tuderman L**, Blobel CP. 2012. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. *J Exp Med* 209:1105-19
9. Fritsch A, Loeckermann S, Kern JS, Braun A, Bösl MR, Bley TA, Schumann H, von Elverfeldt D, Paul D, Erlacher M, Berens von Rautenkamp D, Hausser I, Fässler R, **Bruckner-Tuderman L**. 2008. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. *J Clin Invest* 118:1669-79
10. Franzke CW, Tasanen K, Schäcke H, Zhou Z, Tryggvason K, Mauch C, Zigrino P, Sunnarborg S, Lee DC, Fahrenholz F, **Bruckner-Tuderman L**. 2002. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. *EMBO J* 21:5026-35